We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ventana to Develop Companion Diagnostics for ImmunoGen Anticancer Agents

By LabMedica International staff writers
Posted on 03 Nov 2014
Print article
Ventana Medical Systems, Inc. (Tucson, AZ, USA), member of the Roche Group, has announced a collaboration agreement with ImmunoGen, Inc. (Waltham, MA, USA) to develop biomarker assays and a companion diagnostic (CDx) immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. The goal of the collaboration is to leverage Ventana's expertise in CDx development (from prototyping through regulatory approval and commercialization) to help identify specific patient populations most likely to benefit from ImmunoGen's bio-target directed therapies.

Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1 (FOL1)) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small-cell lung cancers (NSCLC).

"Companion diagnostic tests play a central role in delivering on the promise of personalized healthcare," said Doug Ward, vice president, Ventana Companion Diagnostics, "We're very pleased that this agreement with ImmunoGen should further expand our menu of companion diagnostic test offerings for our pharma and biotech collaborators to benefit patients."

"Our antibody-drug conjugate experimental therapies are designed to hone in on specific targets found on patients' cancer cells," said Dr. Charles Morris, EVP and Chief Development Officer, ImmunoGen. "Companion diagnostics can play an important role in ensuring the patients receiving our agents are ones with the targets and thus the patients most likely to benefit from the treatment. Having this collaboration with Ventana in place now helps us make sure the right patients are receiving IMGN853 during its development."

This pharma collaboration is one of dozens currently underway where the Ventana CDx team is delivering such patient-stratifying diagnostic tools. Additional Ventana collaborations include Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, and MedImmune. Since 2002, Ventana has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize CDx globally.

Related Links:

Ventana Medical Systems
ImmunoGen, Inc.


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.